Optimal Treatment Sequencing in mCRPC Improves Survival

ASCO GU 2017 Data Analysis

• March 14, 2017

Big data analysis from six European countries (44 medical centers, August 2012-July 2016) demonstrates that sequential chemotherapy and hormonal therapy ordering significantly impacts overall survival in mCRPC.

Optimal Treatment Sequence

Docetaxel → Cabazitaxel → Novel ART Agents (abiraterone, enzalutamide alternatives)

Key Efficacy Outcomes by Sequencing

Overall Survival from Docetaxel Initiation:

• Docetaxel → Cabazitaxel: 30.1 months
• Docetaxel → ART → Cabazitaxel: 37.1 months
• Docetaxel → Cabazitaxel → ART: 40.1 months

PSA Response (≥50% decline):

• Group 1: 35.6%
• Group 2: 44.6%
• Group 3: 46.7%

Clinical Characteristics

Median age: 67 years; ECOG 0-1: 89.3%; Pain present: 45.1%; Visceral metastasis: 10.8%

Clinical Significance

Earlier introduction of novel androgen receptor-targeted agents after docetaxel may optimize overall survival in mCRPC compared to sequential use of both chemotherapy agents.

Data Source

ASCO GU 2017; Data: http://meetinglibrary.asco.org/content/178765-197

Informational only; treatment decisions should involve oncology consultation.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1